Man smiling outside

Support intestinal tissue health alongside daily low dose ASA usage

Low dose acetylsalicylic acid (ASA) is widely used and up to 50% of everyday users experience side effects

American associations ACC/AHA1 as well as European associations2 recommend daily use of low dose ASA for primary prevention of cardiovascular issues.

53 million

It is estimated that 53 million U.S. adults are taking ASA everyday (3)


It has been shown that 40-50% of everyday ASA users have gastrointestinal mucosal damage (4)

ASA users are aware of potential gastrointestinal side effects  

51% of consumers are either concerned or have experienced side effects from everyday ASA use. Upset stomach is the most experienced side effect, whereas gastrointestinal ulcers raise the most concern.5


Our unique product – Bif195

As a result of an intense pre-clinical screening program, including state of the art in vitro and in vivo models, Chr. Hansen’s research team identified Bif195 as a promising new candidate to support intestinal tissue health alongside daily low dose ASA usage in healthy volunteers*.


In a golden standard clinical trial published in Gastroenterology 2019, Chr. Hansen’s unique probiotic strain, Bif195, was demonstrated to help protect against small-intestinal damage caused by ASA in healthy volunteers.6

Health benefits

Scientific studies suggest that the probiotic strain Bif195 may:

  • Alleviate potential gastrointestinal side effects from daily low dose ASA usage in healthy volunteers* 
  • Positively impact the integrity of a healthy gastrointestinal tract in daily users of low dose ASA* 
  • Help support integrity of the intestinal lining*


* This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


Please contact your Chr. Hansen sales rep for more information or submit your contact details to be contacted

To view this content consent for marketing cookies needs to be given. Click this text to open the consent form.


1 Arnett et al. 2019, ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
2 rin/
3 Chr. Hansen consumer survey, Dec 2018
4 Bibbins-Domingo et al. 2016, Ann Intern Med.,164:836-845
5 Chr. Hansen consumer survey, Mar 2019 |
6 Mortensen et al., Gastroenterology 2019;157:637–646

The content on this website is presented solely for informational purposes and does not provide you with advice or recommendation of any kind, that can replace advice or recommendation from a healthcare professional. Therefore, you should not act upon information provided on the site without also consulting a healthcare professional. Additionally, no content on this website is intended to be a drug claim such as to diagnose, treat, cure or prevent any disease. Information, including claims, about the probiotic strains on this website is based on applicable U.S. laws and regulations. Information about health benefits is intended for health care and business professionals only. Chr. Hansen probiotic strains have not been evaluated by the U.S. Food and Drug Administration.


Share this with: